{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:48:37Z","timestamp":1782506917061,"version":"3.54.5"},"reference-count":245,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002860","name":"China Sponsorship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002860","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001794","name":"University of Queensland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.actbio.2025.06.016","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T15:24:37Z","timestamp":1750433077000},"page":"101-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Nano-based therapy for type 1 diabetes: from immuno-intervention to insulin delivery"],"prefix":"10.1016","volume":"201","author":[{"given":"Huiwen","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7260-5832","authenticated-orcid":false,"given":"Felicity Y.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.actbio.2025.06.016_bib0001","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2174\/1573396318666220409001955","article-title":"Biology and natural history of type 1 diabetes mellitus","volume":"19","author":"de Azevedo","year":"2023","journal-title":"Curr. Pediatr. Rev."},{"key":"10.1016\/j.actbio.2025.06.016_bib0002","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.16","article-title":"Type 1 diabetes mellitus","volume":"3","author":"Katsarou","year":"2017","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.actbio.2025.06.016_bib0003","doi-asserted-by":"crossref","first-page":"bvab131","DOI":"10.1210\/jendso\/bvab131","article-title":"The epidemiology and genetic analysis of children with idiopathic type 1 diabetes in the State of Qatar","volume":"5","author":"Abdel-Karim","year":"2021","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.actbio.2025.06.016_bib0004","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13098-020-00563-x","article-title":"Non-immune-mediated versus immune-mediated type 1 diabetes: diagnosis and long-term differences-retrospective analysis","volume":"12","author":"Catarino","year":"2020","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.actbio.2025.06.016_bib0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00125-016-4144-8","article-title":"Rebranding asymptomatic type 1 diabetes: the case for autoimmune beta cell disorder as a pathological and diagnostic entity","volume":"60","author":"Bonifacio","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.actbio.2025.06.016_bib0006","unstructured":"D.J. Magliano, E.J. Boyko, IDF DIABETES ATLAS, Brussels, 2021."},{"key":"10.1016\/j.actbio.2025.06.016_bib0007","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1097\/MS9.0000000000000894","article-title":"Comprehensive review of diabetic ketoacidosis: an update","volume":"85","author":"Elendu","year":"2023","journal-title":"Ann. Med. Surg. (Lond.)"},{"key":"10.1016\/j.actbio.2025.06.016_bib0008","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(24)02317-1","article-title":"Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants","volume":"404","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.actbio.2025.06.016_bib0009","article-title":"Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025","volume":"10","author":"Lin","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.actbio.2025.06.016_bib0010","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s13098-024-01491-w","article-title":"Time trends and advances in the management of global, regional, and national diabetes in adolescents and young adults aged 10-24 years, 1990-2021: analysis for the global burden of disease study 2021","volume":"16","author":"Liu","year":"2024","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.actbio.2025.06.016_bib0011","article-title":"Global, regional, and national burden of type 1 diabetes in adolescents and young adults","author":"Gong","year":"2024","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.actbio.2025.06.016_bib0012","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/pedi.13025","article-title":"Incidence of type 1 diabetes in 0 to 14 year olds in Australia from 2002 to 2017","volume":"21","author":"Haynes","year":"2020","journal-title":"Pediatr. Diabetes."},{"key":"10.1016\/j.actbio.2025.06.016_bib0013","doi-asserted-by":"crossref","first-page":"e3770","DOI":"10.1002\/dmrr.3770","article-title":"Type 1 diabetes: a new vision of the disease based on endotypes","volume":"40","author":"Weston","year":"2024","journal-title":"Diabetes. Metab. Res. Rev."},{"key":"10.1016\/j.actbio.2025.06.016_bib0014","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1086\/302283","article-title":"The predisposition to type 1 diabetes linked to the human leukocyte antigen complex includes at least one non-class II gene","volume":"64","author":"Lie","year":"1999","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.actbio.2025.06.016_bib0015","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3892\/etm.2023.12160","article-title":"Methylation haplotypes of the insulin gene promoter in children and adolescents with type 1 diabetes: can a dimensionality reduction approach predict the disease?","volume":"26","author":"Kotanidou","year":"2023","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.actbio.2025.06.016_bib0016","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1365-2249.1997.t01-1-512-ce1410.x","article-title":"CTLA-4 gene polymorphism confers susceptibility to insulin-dependent diabetes mellitus (IDDM) independently from age and from other genetic or immune disease markers. The Belgian Diabetes Registry","volume":"110","author":"Van der Auwera","year":"1997","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0017","unstructured":"M.J. Redondo, S. Onengut-Gumuscu, K.J. Gaulton, Genetics of type 1 diabetes, in: J.M. Lawrence, S.S. Casagrande, W.H. Herman, D.J. Wexler, W.T. Cefalu (Eds.) Diabetes in America, Bethesda (MD), 2023."},{"key":"10.1016\/j.actbio.2025.06.016_bib0018","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.immuni.2010.03.018","article-title":"Prediction and pathogenesis in type 1 diabetes","volume":"32","author":"Ziegler","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.actbio.2025.06.016_bib0019","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/dmrr.998","article-title":"Role of insulin autoantibody affinity as a predictive marker for type 1 diabetes in young children with HLA-conferred disease susceptibility","volume":"25","author":"Siljander","year":"2009","journal-title":"Diabetes. Metab. Res. Rev."},{"key":"10.1016\/j.actbio.2025.06.016_bib0020","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1358\/dof.2011.36.11.1710754","article-title":"GAD65 autoantibodies and its role as biomarker of type 1 diabetes and latent autoimmune Diabetes in adults (LADA)","volume":"36","author":"Towns","year":"2011","journal-title":"Drugs Fut."},{"key":"10.1016\/j.actbio.2025.06.016_bib0021","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.2337\/db18-1351","article-title":"Type 1 diabetes TrialNet study, autoantibodies directed toward a novel IA-2 variant protein enhance prediction of Type 1 diabetes","volume":"68","author":"Acevedo-Calado","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.actbio.2025.06.016_bib0022","article-title":"The role of heat shock proteins in type 1 diabetes","volume":"11","author":"Moin","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0023","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaut.2013.10.003","article-title":"Chromogranin A is a T cell antigen in human type 1 diabetes","volume":"50","author":"Gottlieb","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.actbio.2025.06.016_bib0024","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s00125-019-04975-x","article-title":"What has zinc transporter 8 autoimmunity taught us about type 1 diabetes?","volume":"62","author":"Williams","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.actbio.2025.06.016_bib0025","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad160","article-title":"Understanding islet autoantibodies in prediction of type 1 diabetes","volume":"8","author":"Jia","year":"2023","journal-title":"J. Endocrine Soc."},{"key":"10.1016\/j.actbio.2025.06.016_bib0026","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2337\/dc15-1419","article-title":"Staging presymptomatic Type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association","volume":"38","author":"Insel","year":"2015","journal-title":"Diabet. Care"},{"key":"10.1016\/j.actbio.2025.06.016_bib0027","first-page":"17","article-title":"Autoantibodies in type 1 diabetes: prevalence and clinical profiles","author":"Hazime","year":"2025","journal-title":"Diabet. Epidemiol. Man."},{"key":"10.1016\/j.actbio.2025.06.016_bib0028","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2035117","article-title":"Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders - advances and challenges","volume":"18","author":"Goswami","year":"2022","journal-title":"Hum. Vaccin. ImmunOther."},{"key":"10.1016\/j.actbio.2025.06.016_bib0029","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1146\/annurev.immunol.15.1.821","article-title":"Capture and processing of exogenous antigens for presentation on MHC molecules","volume":"15","author":"Watts","year":"1997","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0030","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1182\/blood-2009-06-225417","article-title":"Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation","volume":"115","author":"Aubin","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2025.06.016_bib0031","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.smim.2017.09.007","article-title":"Modulating the immune system through nanotechnology","volume":"34","author":"Dacoba","year":"2017","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0032","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/imm.12360","article-title":"Soluble MHC-II proteins promote suppressive activity in CD4+ T cells","volume":"144","author":"Bakela","year":"2015","journal-title":"Immunology"},{"key":"10.1016\/j.actbio.2025.06.016_bib0033","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1084\/jem.192.1.145","article-title":"Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli","volume":"192","author":"Schuurhuis","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.actbio.2025.06.016_bib0034","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.4110\/in.2024.24.e42","article-title":"T cell resistance: on the mechanisms of T cell non-activation","volume":"24","author":"Beckers","year":"2024","journal-title":"Immune Netw."},{"key":"10.1016\/j.actbio.2025.06.016_bib0035","first-page":"124","article-title":"Anti-IgM treatment of C57BL\/6-1pr\/1pr mice: depletion of B cells reduces 1pr gene-induced lymphoproliferation and mononuclear cell vasculitis","volume":"77","author":"Cerny","year":"1989","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0036","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2337\/diab.46.6.941","article-title":"B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice","volume":"46","author":"Noorchashm","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.actbio.2025.06.016_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.954936","article-title":"Role of B cells as antigen presenting cells","volume":"13","author":"Rastogi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0038","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.immuni.2008.03.016","article-title":"Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction","volume":"28","author":"Tang","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.actbio.2025.06.016_bib0039","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.3389\/fimmu.2017.02001","article-title":"CD4(+) T helper cells play a key role in maintaining diabetogenic CD8(+) T cell function in the pancreas","volume":"8","author":"Espinosa-Carrasco","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0040","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41574-020-00443-4","article-title":"Type 1 diabetes mellitus as a disease of the \u03b2-cell (do not blame the immune system?)","volume":"17","author":"Roep","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0041","doi-asserted-by":"crossref","DOI":"10.3390\/biom10121681","article-title":"Beta cell therapies for preventing type 1 diabetes: from bench to bedside","volume":"10","author":"Brawerman","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.actbio.2025.06.016_bib0042","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1016\/j.cell.2025.02.018","article-title":"Genetic protection from type 1 diabetes resulting from accelerated insulin mRNA decay","volume":"188","author":"van Tienhoven","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.actbio.2025.06.016_bib0043","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2337\/dbi17-0030","article-title":"Immune recognition of \u03b2-cells: neoepitopes as key players in the loss of tolerance","volume":"67","author":"James","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.actbio.2025.06.016_bib0044","article-title":"The role of beta cell stress and neo-epitopes in the immunopathology of type 1 diabetes","volume":"11","author":"Piganelli","year":"2020","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.actbio.2025.06.016_bib0045","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.2337\/db24-0163","article-title":"Revisiting the pattern of loss of \u03b2-cell function in preclinical type 1 diabetes","volume":"73","author":"Martino","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.actbio.2025.06.016_bib0046","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/MED.0000000000000548","article-title":"The role of beta-cell dysfunction in early type 1 diabetes","volume":"27","author":"Sims","year":"2020","journal-title":"Curr. Opin. Endocrinol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0047","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a007807","article-title":"Breakdown in peripheral tolerance in type 1 diabetes in mice and humans","volume":"2","author":"Jeker","year":"2012","journal-title":"Cold. Spring. Harb. Perspect. Med."},{"key":"10.1016\/j.actbio.2025.06.016_bib0048","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/cei\/uxac115","article-title":"Antigen-specific immunotherapy to restore antigen-specific tolerance in type 1 diabetes and Graves' disease","volume":"211","author":"Zala","year":"2023","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0049","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/TP.0b013e3181e7e54f","article-title":"The role of the thymus in tolerance","volume":"90","author":"Griesemer","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.actbio.2025.06.016_bib0050","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ng0397-289","article-title":"Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus","volume":"15","author":"Vafiadis","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.actbio.2025.06.016_bib0051","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1084\/jem.20120905","article-title":"Autoreactive T cells bypass negative selection and respond to self-antigen stimulation during infection","volume":"209","author":"Enouz","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.actbio.2025.06.016_bib0052","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006957","article-title":"T-cell tolerance: central and peripheral","volume":"4","author":"Xing","year":"2012","journal-title":"Cold. Spring. Harb. Perspect. Biol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0053","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltad007","article-title":"Treg-based immunotherapy for antigen-specific immune suppression and stable tolerance induction: a perspective","volume":"3","author":"Sakaguchi","year":"2023","journal-title":"ImmunOther Adv."},{"key":"10.1016\/j.actbio.2025.06.016_bib0054","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1084\/jem.192.2.295","article-title":"Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation","volume":"192","author":"Read","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.actbio.2025.06.016_bib0055","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1159\/000315084","article-title":"Oxidized low-density lipoprotein-induced proinflammatory cytokine response in macrophages are suppressed by CD4CD25(+)Foxp3(+) regulatory T cells through downregulating toll like receptor 2-mediated activation of NF-kappaB","volume":"25","author":"Li","year":"2010","journal-title":"Cell Physiol. Biochem."},{"key":"10.1016\/j.actbio.2025.06.016_bib0056","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+CD25+ regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0057","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0105-2896.2006.00427.x","article-title":"Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease","volume":"212","author":"Sakaguchi","year":"2006","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.actbio.2025.06.016_bib0058","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.2337\/diabetes.54.12.3395","article-title":"On the edge of autoimmunity: t-cell stimulation by steady-state dendritic cells prevents autoimmune diabetes","volume":"54","author":"Bruder","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.actbio.2025.06.016_bib0059","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1046\/j.1440-1711.2002.01115.x","article-title":"Immature, but not inactive: the tolerogenic function of immature dendritic cells","volume":"80","author":"Mahnke","year":"2002","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0060","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltad012","article-title":"Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administration","volume":"3","author":"Mansilla","year":"2023","journal-title":"ImmunOther Adv."},{"key":"10.1016\/j.actbio.2025.06.016_bib0061","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28186624","article-title":"Emerging applications of nanotechnology in healthcare and medicine","volume":"28","author":"Malik","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.actbio.2025.06.016_bib0062","article-title":"Reactive oxygen species-based nanomaterials for cancer therapy","volume":"9","author":"Li","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.actbio.2025.06.016_bib0063","doi-asserted-by":"crossref","first-page":"5930","DOI":"10.1021\/acsabm.9b00852","article-title":"Investigating the use of layered double hydroxide nanoparticles as carriers of metal oxides for theranostics of ROS-related diseases","volume":"2","author":"Liu","year":"2019","journal-title":"ACS Appl. Bio. Mater."},{"key":"10.1016\/j.actbio.2025.06.016_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119986","article-title":"Biomimetic carbon monoxide nanogenerator ameliorates streptozotocin induced type 1 diabetes in mice","volume":"245","author":"Zhang","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2025.06.016_bib0065","doi-asserted-by":"crossref","DOI":"10.3389\/fnano.2024.1456939","article-title":"Recent advances in surface decoration of nanoparticles in drug delivery","volume":"6","author":"Ly","year":"2024","journal-title":"Front. Nanotechnol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0066","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0067","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil(R)\u2013the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control Release"},{"key":"10.1016\/j.actbio.2025.06.016_bib0068","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/3687700","article-title":"Paclitaxel: application in modern oncology and nanomedicine-based cancer therapy","author":"Sharifi-Rad","year":"2021","journal-title":"Oxid. Med. Cell Longev."},{"key":"10.1016\/j.actbio.2025.06.016_bib0069","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2021.101142","article-title":"Role of nanotechnology behind the success of mRNA vaccines for COVID-19","volume":"38","author":"Khurana","year":"2021","journal-title":"Nano Today"},{"key":"10.1016\/j.actbio.2025.06.016_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103393","article-title":"Progress in oral insulin delivery by PLGA nanoparticles for the management of diabetes","volume":"28","author":"Pang","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.actbio.2025.06.016_bib0071","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25137028","article-title":"Nanomedicine in the treatment of diabetes","volume":"25","author":"Andreadi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.actbio.2025.06.016_bib0072","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1021\/acsptsci.3c00218","article-title":"Targeting \u03b2 cells with Cathelicidin nanomedicines improves insulin function and pancreas regeneration in type 1 diabetic rats","volume":"6","author":"Cristelo","year":"2023","journal-title":"ACS Pharmacol. Transl."},{"key":"10.1016\/j.actbio.2025.06.016_bib0073","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s00125-024-06356-5","article-title":"Active targeting of type 1 diabetes therapies to pancreatic beta cells using nanocarriers","volume":"68","author":"Collins","year":"2025","journal-title":"Diabetologia"},{"key":"10.1016\/j.actbio.2025.06.016_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2021.101063","article-title":"Delivery of therapeutic agents and cells to pancreatic islets: towards a new era in the treatment of diabetes","volume":"83","author":"Zeynaloo","year":"2022","journal-title":"Mol. Aspects. Med."},{"key":"10.1016\/j.actbio.2025.06.016_bib0075","first-page":"16","article-title":"Nanomaterial-driven precision immunomodulation: a new paradigm in therapeutic interventions","author":"Aljabali","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.actbio.2025.06.016_bib0076","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltab009","article-title":"Advancement of antigen-specific immunotherapy: knowledge transfer between allergy and autoimmunity","volume":"1","author":"Richardson","year":"2021","journal-title":"ImmunOther Adv."},{"key":"10.1016\/j.actbio.2025.06.016_bib0077","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0078","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/eji.200737984","article-title":"Nanoparticles target distinct dendritic cell populations according to their size","volume":"38","author":"Manolova","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0079","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.nano.2014.11.004","article-title":"Uptake efficiency of surface modified gold nanoparticles does not correlate with functional changes and cytokine secretion in human dendritic cells in vitro","volume":"11","author":"Fytianos","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.actbio.2025.06.016_bib0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41565-020-00810-2","article-title":"Inducing immune tolerance with dendritic cell-targeting nanomedicines","volume":"16","author":"Cifuentes-Rius","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0081","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/adhm.201200441","article-title":"Targeting dendritic cells: the role of specific receptors in the internalization of polymer capsules","volume":"2","author":"Mintern","year":"2013","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.actbio.2025.06.016_bib0082","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3389\/fimmu.2018.00990","article-title":"Mouse DC-SIGN\/CD209a as target for antigen delivery and adaptive immunity","volume":"9","author":"Schetters","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0083","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1021\/acsbiomaterials.7b00831","article-title":"Latent, immunosuppressive nature of poly(lactic-co-glycolic acid) microparticles","volume":"4","author":"Allen","year":"2018","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.actbio.2025.06.016_bib0084","doi-asserted-by":"crossref","first-page":"465","DOI":"10.4049\/jimmunol.2200208","article-title":"Tolerogenic immune-modifying nanoparticles encapsulating multiple recombinant pancreatic beta cell proteins prevent onset and progression of type 1 diabetes in nonobese diabetic mice","volume":"209","author":"Podojil","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0085","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1021\/acs.molpharmaceut.0c00525","article-title":"Old dog new tricks: PLGA microparticles as an adjuvant for insulin peptide fragment-induced immune tolerance against type 1 diabetes","volume":"17","author":"Liu","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.actbio.2025.06.016_bib0086","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jaut.2017.12.010","article-title":"Tolerogenic Ag-PLG nanoparticles induce tregs to suppress activated diabetogenic CD4 and CD8 T cells","volume":"89","author":"Prasad","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.actbio.2025.06.016_bib0087","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4049\/jimmunol.1900127","article-title":"Nanoparticles containing an insulin-ChgA hybrid peptide protect from transfer of autoimmune diabetes by shifting the balance between effector T cells and regulatory T cells","volume":"203","author":"Jamison","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0088","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2337\/db20-1170","article-title":"Tolerogenic delivery of a hybrid insulin peptide markedly prolongs islet graft survival in the NOD mouse","volume":"71","author":"Jamison","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.actbio.2025.06.016_bib0089","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202301096","article-title":"Peptide hydrogels as immunomaterials and their use in cancer immunotherapy delivery","volume":"12","author":"Falcone","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.actbio.2025.06.016_bib0090","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1039\/D4BM00865K","article-title":"Peptide-based supramolecular hydrogels and their biotherapeutic applications","volume":"12","author":"Wu","year":"2024","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.actbio.2025.06.016_bib0091","article-title":"An insulin-inspired supramolecular hydrogel for prevention of type 1 diabetes","volume":"8","author":"Liu","year":"2021","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.actbio.2025.06.016_bib0092","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.2337\/db08-0138","article-title":"Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells","volume":"57","author":"Monti","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.actbio.2025.06.016_bib0093","article-title":"IL-10 deficiency accelerates type 1 diabetes development via modulation of innate and adaptive immune cells and gut microbiota in BDC2.5 NOD mice","volume":"12","author":"Huang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0094","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/db11-1213","article-title":"Central role for interleukin-2 in type 1 diabetes","volume":"61","author":"Hulme","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.actbio.2025.06.016_bib0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.586220","article-title":"Arrest in the progression of type 1 diabetes at the mid-stage of insulitic autoimmunity using an autoantigen-decorated all-trans retinoic acid and transforming growth factor beta-1 single microparticle formulation","volume":"12","author":"Phillips","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0096","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clim.2008.12.001","article-title":"Modulation of dendritic cells using granulocyte-macrophage colony-stimulating factor (GM-CSF) delays type 1 diabetes by enhancing CD4+CD25+ regulatory T cell function","volume":"131","author":"Cheatem","year":"2009","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0097","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.thromres.2018.10.026","article-title":"Phosphatidylserine expressing microvesicles in relation to microvascular complications in type 1 diabetes","volume":"172","author":"Bergen","year":"2018","journal-title":"Thromb. Res."},{"key":"10.1016\/j.actbio.2025.06.016_bib0098","doi-asserted-by":"crossref","first-page":"ra61","DOI":"10.1126\/scisignal.aad0612","article-title":"Tolerogenic nanoparticles inhibit T cell-mediated autoimmunity through SOCS2","volume":"9","author":"Yeste","year":"2016","journal-title":"Sci. Signal."},{"key":"10.1016\/j.actbio.2025.06.016_bib0099","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2012.01.013","article-title":"Controlled release formulations of IL-2, TGF-beta1 and rapamycin for the induction of regulatory T cells","volume":"159","author":"Jhunjhunwala","year":"2012","journal-title":"J. Control Release"},{"key":"10.1016\/j.actbio.2025.06.016_bib0100","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1126\/science.1215135","article-title":"Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity","volume":"335","author":"Lamming","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.actbio.2025.06.016_bib0101","article-title":"Particle-based therapies for antigen specific treatment of type 1 diabetes","volume":"631","author":"Lukesh","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.actbio.2025.06.016_bib0102","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.clim.2015.03.023","article-title":"A combination dual-sized microparticle system modulates dendritic cells and prevents type 1 diabetes in prediabetic NOD mice","volume":"160","author":"Lewis","year":"2015","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0103","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3389\/fimmu.2018.00253","article-title":"Phosphatidylserine-liposomes promote tolerogenic features on dendritic cells in Human type 1 diabetes by apoptotic mimicry","volume":"9","author":"Rodriguez-Fernandez","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0104","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1007\/s00125-018-4593-3","article-title":"Targeted delivery of antigen to intestinal dendritic cells induces oral tolerance and prevents autoimmune diabetes in NOD mice","volume":"61","author":"Chen","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.actbio.2025.06.016_bib0105","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.3390\/molecules14124892","article-title":"Phospholipids: key players in apoptosis and immune regulation","volume":"14","author":"Chaurio","year":"2009","journal-title":"Molecules"},{"key":"10.1016\/j.actbio.2025.06.016_bib0106","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00403-007-0770-9","article-title":"Artificial phosphatidylserine liposome mimics apoptotic cells in inhibiting maturation and immunostimulatory function of murine myeloid dendritic cells in response to 1-chloro-2,4-dinitrobenze in vitro","volume":"299","author":"Shi","year":"2007","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.actbio.2025.06.016_bib0107","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127057","article-title":"Use of autoantigen-loaded phosphatidylserine-liposomes to arrest autoimmunity in type 1 diabetes","volume":"10","author":"Pujol-Autonell","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.actbio.2025.06.016_bib0108","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/21691401.2019.1699812","article-title":"Preclinical evaluation of antigen-specific nanotherapy based on phosphatidylserine-liposomes for type 1 diabetes","volume":"48","author":"Villalba","year":"2020","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0109","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201800341","article-title":"Prevention of type 1 diabetes with acetalated dextran microparticles containing rapamycin and pancreatic peptide P31","volume":"7","author":"Chen","year":"2018","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.actbio.2025.06.016_bib0110","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00125-019-4822-4","article-title":"Beta cells in type 1 diabetes: mass and function; sleeping or dead?","volume":"62","author":"Oram","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.actbio.2025.06.016_bib0111","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fendo.2020.00258","article-title":"Repurposed analog of GLP-1 ameliorates hyperglycemia in type 1 diabetic mice through pancreatic cell reprogramming","volume":"11","author":"Villalba","year":"2020","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.actbio.2025.06.016_bib0112","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.2337\/db18-0155","article-title":"Glucagon-like peptide 1 increases beta-cell regeneration by promoting alpha- to beta-cell transdifferentiation","volume":"67","author":"Lee","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.actbio.2025.06.016_bib0113","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-76041-1","article-title":"Antigen-specific immunotherapy combined with a regenerative drug in the treatment of experimental type 1 diabetes","volume":"10","author":"Villalba","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.actbio.2025.06.016_bib0114","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jconrel.2024.09.020","article-title":"LNP-mRNA vaccine prevents type 1 diabetes in non-obese diabetes mice","volume":"375","author":"Chen","year":"2024","journal-title":"J. Control Release"},{"key":"10.1016\/j.actbio.2025.06.016_bib0115","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nature16962","article-title":"Expanding antigen-specific regulatory networks to treat autoimmunity","volume":"530","author":"Clemente-Casares","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.actbio.2025.06.016_bib0116","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1177722","article-title":"Transcriptional re-programming of insulin B-chain epitope-specific T-follicular helper cells into anti-diabetogenic T-regulatory type-1 cells","volume":"14","author":"Sole","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0117","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.immuni.2010.03.015","article-title":"Reversal of autoimmunity by boosting memory-like autoregulatory T cells","volume":"32","author":"Tsai","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.actbio.2025.06.016_bib0118","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/icb.2013.20","article-title":"Autoimmunity treatment using pMHC-NP-based therapy: designing nanoparticle treatment of autoimmunity with quantitative biology","volume":"91","author":"Schnell","year":"2013","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2019.06.001","article-title":"Antibody therapeutics and immunoregulation in cancer and autoimmune disease","volume":"64","author":"Yasunaga","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0120","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/978-1-4939-8958-4_11","article-title":"Antigen-specific Human monoclonal antibodies from transgenic mice","volume":"1904","author":"Mompo","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0121","first-page":"15","article-title":"Fc-engineered therapeutic antibodies: recent advances and future directions","author":"Abdeldaim","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.actbio.2025.06.016_bib0122","article-title":"Evolving antibody therapies for the treatment of type 1 diabetes","volume":"11","author":"Ke","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0123","article-title":"Inhibition of increased circulating tfh cell by anti-CD20 monoclonal antibody in patients with type 1 diabetes","volume":"8","author":"Xu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.actbio.2025.06.016_bib0124","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2174\/2772270817666221122103029","article-title":"Narrative review of anti-CD3 antibody and anti-CD20 antibody: immunotherapeutic strategies to treat and prevent type 1 diabetes","volume":"17","author":"Kashalikar","year":"2023","journal-title":"Recent. Adv. Inflamm. Allergy Drug Discov."},{"key":"10.1016\/j.actbio.2025.06.016_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117985","article-title":"Combination therapy with anti-CD20 mAb and IL-10 gene to reverse type 1 diabetes by attenuating pancreatitis and inhibiting apoptosis in NOD mice","volume":"256","author":"Li","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.actbio.2025.06.016_bib0126","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJM200210033471416","article-title":"Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus","volume":"347","author":"Killestein","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.actbio.2025.06.016_bib0127","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1073\/pnas.91.1.123","article-title":"Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice","volume":"91","author":"Chatenoud","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.actbio.2025.06.016_bib0128","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.2337\/db13-0345","article-title":"Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders","volume":"62","author":"Herold","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.actbio.2025.06.016_bib0129","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1172\/JCI23961","article-title":"TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ tregs","volume":"115","author":"Bisikirska","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.actbio.2025.06.016_bib0130","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.actbio.2025.06.016_bib0131","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/00007890-198904000-00008","article-title":"Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients","volume":"47","author":"Abramowicz","year":"1989","journal-title":"Transplantation"},{"key":"10.1016\/j.actbio.2025.06.016_bib0132","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ajpath.2020.10.009","article-title":"High endothelial venules accelerate naive T cell recruitment by tumor necrosis factor-mediated R-ras upregulation","volume":"191","author":"Sawada","year":"2021","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0133","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.it.2012.02.007","article-title":"Lymph node homing of T cells and dendritic cells via afferent lymphatics","volume":"33","author":"Forster","year":"2012","journal-title":"Trends. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0134","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1084\/jem.20011353","article-title":"Pancreatic lymph nodes are required for priming of beta cell reactive T cells in NOD mice","volume":"196","author":"Gagnerault","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.actbio.2025.06.016_bib0135","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/cei.13353","article-title":"Immune cell trafficking to the islets during type 1 diabetes","volume":"198","author":"Sandor","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0136","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202300812","article-title":"Nanotargeted delivery of Immune therapeutics in type 1 diabetes","volume":"35","author":"Jung","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2025.06.016_bib0137","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1084\/jem.180.6.2219","article-title":"Sulfation-dependent recognition of high endothelial venules (HEV)-ligands by L-selectin and MECA 79, and adhesion-blocking monoclonal antibody","volume":"180","author":"Hemmerich","year":"1994","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.actbio.2025.06.016_bib0138","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: an \"enigma\" of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.actbio.2025.06.016_bib0139","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2337\/dc13-0626","article-title":"C.D.S.G. Type 1 diabetes TrialNet anti, B-lymphocyte depletion with rituximab and beta-cell function: two-year results","volume":"37","author":"Pescovitz","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.actbio.2025.06.016_bib0140","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"C.D.S.G. Type 1 diabetes TrialNet Anti, Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.actbio.2025.06.016_bib0141","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1172\/JCI83840","article-title":"Rituximab does not reset defective early B cell tolerance checkpoints","volume":"126","author":"Chamberlain","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.actbio.2025.06.016_bib0142","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1470677","article-title":"TNF-alpha inhibitors for type 1 diabetes: exploring the path to a pivotal clinical trial","volume":"15","author":"Bazile","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0143","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2337\/dc22-2200","article-title":"G. Type 1 diabetes TrialNet study, abatacept for delay of type 1 diabetes progression in stage 1 relatives at risk: a randomized, double-masked, controlled trial","volume":"46","author":"Russell","year":"2023","journal-title":"Diabet. Care"},{"key":"10.1016\/j.actbio.2025.06.016_bib0144","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s12951-021-01096-9","article-title":"Biomimetic 2D layered double hydroxide nanocomposites for hyperthermia-facilitated homologous targeting cancer photo-chemotherapy","volume":"19","author":"Wang","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0145","doi-asserted-by":"crossref","DOI":"10.1093\/nsr\/nwae018","article-title":"Lymph node-biomimetic scaffold boosts CAR-T therapy against solid tumor","volume":"11","author":"Liao","year":"2024","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.actbio.2025.06.016_bib0146","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40824-021-00246-2","article-title":"Immune cell targeting nanoparticles: a review","volume":"25","author":"Lee","year":"2021","journal-title":"Biomater. Res."},{"key":"10.1016\/j.actbio.2025.06.016_bib0147","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-022-01528-6","article-title":"RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics","volume":"21","author":"Pandey","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.actbio.2025.06.016_bib0148","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.4049\/jimmunol.1203233","article-title":"Antisense oligonucleotide treatment enhances the recovery of acute lung injury through IL-10-secreting M2-like macrophage-induced expansion of CD4+ regulatory T cells","volume":"190","author":"Guo","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0149","article-title":"The role of MicroRNAs in regulatory T cells","author":"Liu","year":"2020","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.actbio.2025.06.016_bib0150","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2337\/db21-0327","article-title":"Multicomponent plasmid protects mice from spontaneous autoimmune diabetes","volume":"71","author":"Pagni","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.actbio.2025.06.016_bib0151","series-title":"A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041 Administered Subcutaneously to Patients With Type 1 Diabetes Mellitus","year":"2025"},{"key":"10.1016\/j.actbio.2025.06.016_bib0152","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.canlet.2019.04.040","article-title":"Nanoparticles for nucleic acid delivery: applications in cancer immunotherapy","volume":"458","author":"Mukalel","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.actbio.2025.06.016_bib0153","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11095-008-9710-4","article-title":"Poly (lactide-co-glycolide)-polymethacrylate nanoparticles for intramuscular delivery of plasmid encoding interleukin-10 to prevent autoimmune diabetes in mice","volume":"26","author":"Basarkar","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.actbio.2025.06.016_bib0154","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.2337\/db07-0507","article-title":"A microsphere-based vaccine prevents and reverses new-onset autoimmune diabetes","volume":"57","author":"Phillips","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.actbio.2025.06.016_bib0155","doi-asserted-by":"crossref","first-page":"48259","DOI":"10.1021\/acsami.0c10885","article-title":"An all-in-one nanomedicine consisting of CRISPR-Cas9 and an autoantigen peptide for restoring specific immune tolerance","volume":"12","author":"Luo","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.actbio.2025.06.016_bib0156","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0157","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","article-title":"Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy","volume":"12","author":"Yang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2025.06.016_bib0158","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s12272-010-1115-3","article-title":"Forced expression of programmed death-1 gene on T cell decreased the incidence of type 1 diabetes","volume":"33","author":"Won","year":"2010","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.actbio.2025.06.016_bib0159","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7543","article-title":"PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes","volume":"9","author":"Ben Nasr","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.actbio.2025.06.016_bib0160","article-title":"Engineered PD-L1-expressing platelets reverse new-onset type 1 diabetes","volume":"32","author":"Zhang","year":"2020","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2025.06.016_bib0161","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2337\/db23-0987","article-title":"Bioengineered artificial extracellular vesicles presenting PD-L1 and gal-9 ameliorate new-onset type 1 diabetes","volume":"73","author":"Yang","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.actbio.2025.06.016_bib0162","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.cmet.2016.10.009","article-title":"Immunotherapy for type 1 diabetes: why do current protocols not halt the underlying disease process?","volume":"25","author":"Kolb","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.actbio.2025.06.016_bib0163","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/dom.15357","article-title":"Effect of artificial pancreas system use on glycaemic control among pregnant women with type 1 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"26","author":"Lei","year":"2024","journal-title":"Diabet. Obes. Metabol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0164","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s11517-024-03042-x","article-title":"Recent advances in the precision control strategy of artificial pancreas","volume":"62","author":"Ming","year":"2024","journal-title":"Med. Biol. Eng. Comput."},{"key":"10.1016\/j.actbio.2025.06.016_bib0165","doi-asserted-by":"crossref","first-page":"813","DOI":"10.4093\/dmj.2021.0177","article-title":"Current Advances of artificial pancreas systems: a comprehensive review of the clinical evidence","volume":"45","author":"Moon","year":"2021","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.actbio.2025.06.016_bib0166","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S2213-8587(24)00220-1","article-title":"Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1","volume":"12","author":"Bergenstal","year":"2024","journal-title":"Lancet Diabetes. Endocrinol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0167","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1056\/NEJMoa2403953","article-title":"Q.-. investigators, insulin efsitora versus degludec in type 2 diabetes without previous insulin treatment","volume":"391","author":"Wysham","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.actbio.2025.06.016_bib0168","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00128071-200304100-00001","article-title":"Skin-related complications of insulin therapy: epidemiology and emerging management strategies","volume":"4","author":"Richardson","year":"2003","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0169","doi-asserted-by":"crossref","DOI":"10.1530\/EDM-14-0073","article-title":"Painful fat necrosis resulting from insulin injections","author":"Hanson","year":"2014","journal-title":"Endocrinol. Diabetes. Metab. Case Rep."},{"key":"10.1016\/j.actbio.2025.06.016_bib0170","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.apsb.2024.02.019","article-title":"Oral peptide therapeutics for diabetes treatment: state-of-the-art and future perspectives","volume":"14","author":"Ding","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.actbio.2025.06.016_bib0171","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.202400547","article-title":"Enhanced epithelial cell uptake of glycol chitosan-coated PLGA nanoparticles for oral drug delivery","author":"Pang","year":"2025","journal-title":"Adv. Therap."},{"key":"10.1016\/j.actbio.2025.06.016_bib0172","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s13346-021-00908-7","article-title":"Current approaches in lipid-based nanocarriers for oral drug delivery","volume":"11","author":"Plaza-Oliver","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.actbio.2025.06.016_bib0173","first-page":"48","article-title":"Lipid-based nanoparticles as oral drug delivery systems: overcoming poor gastrointestinal absorption and enhancing bioavailability of peptide and protein therapeutics","volume":"14","author":"Mehrdadi","year":"2024","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.actbio.2025.06.016_bib0174","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201801123","article-title":"Protein corona liposomes achieve efficient oral insulin delivery by overcoming mucus and epithelial barriers","volume":"8","author":"Wang","year":"2019","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.actbio.2025.06.016_bib0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2020.111203","article-title":"Folate targeted PEGylated liposomes for the oral delivery of insulin: in vitro and in vivo studies","volume":"194","author":"Yazdi","year":"2020","journal-title":"Colloids. Surf. B Biointerfaces."},{"key":"10.1016\/j.actbio.2025.06.016_bib0176","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijpharm.2004.12.030","article-title":"New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin","volume":"296","author":"Garcia-Fuentes","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.actbio.2025.06.016_bib0177","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/B978-0-12-391860-4.00015-X","article-title":"Chitosan-coated solid lipid nanoparticles for insulin delivery","volume":"508","author":"Fonte","year":"2012","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0178","doi-asserted-by":"crossref","first-page":"43","DOI":"10.5530\/jyp.2021.13.10","article-title":"Oral insulin delivery by Chitosan coated solid lipid nanoparticles: ex vivo and in vivo studies","volume":"13","author":"Anchan","year":"2021","journal-title":"J. Young. Pharm."},{"key":"10.1016\/j.actbio.2025.06.016_bib0179","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.xphs.2018.04.011","article-title":"Bioadhesive chitosan-coated cationic nanoliposomes with improved insulin encapsulation and prolonged oral hypoglycemic effect in diabetic mice","volume":"107","author":"Shalaby","year":"2018","journal-title":"J. Pharm. Sci.-Us."},{"key":"10.1016\/j.actbio.2025.06.016_bib0180","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ejps.2012.04.002","article-title":"Improved oral bioavailability of alendronate via the mucoadhesive liposomal delivery system","volume":"46","author":"Han","year":"2012","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.actbio.2025.06.016_bib0181","doi-asserted-by":"crossref","DOI":"10.1515\/ntrev-2023-0205","article-title":"A comprehensive review of oral chitosan drug delivery systems: applications for oral insulin delivery","volume":"13","author":"Alfatama","year":"2024","journal-title":"Nanotechnol. Rev."},{"key":"10.1016\/j.actbio.2025.06.016_bib0182","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.125779","article-title":"Enhance the oral insulin delivery route using a modified chitosan-based formulation fabricated by microwave","volume":"247","author":"AlSalem","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0183","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.biomaterials.2017.03.028","article-title":"Scalable fabrication of size-controlled chitosan nanoparticles for oral delivery of insulin","volume":"130","author":"He","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2025.06.016_bib0184","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ijbiomac.2014.08.040","article-title":"pH-sensitive chitosan\/alginate core-shell nanoparticles for efficient and safe oral insulin delivery","volume":"72","author":"Mukhopadhyay","year":"2015","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0185","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ijbiomac.2020.02.079","article-title":"Biodistribution and pharmacokinetics of thiolated chitosan nanoparticles for oral delivery of insulin in vivo","volume":"150","author":"Sudhakar","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0186","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.136549","article-title":"Colonic targeting insulin-loaded trimethyl chitosan nanoparticles coated pectin for oral delivery: in vitro and In vivo studies","volume":"281","author":"Seyam","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0187","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijbiomac.2018.12.182","article-title":"Development of mutlifunctional nanoparticles self-assembled from trimethyl chitosan and fucoidan for enhanced oral delivery of insulin","volume":"126","author":"Tsai","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0188","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jconrel.2015.12.008","article-title":"Efficient mucus permeation and tight junction opening by dissociable \"mucus-inert\" agent coated trimethyl chitosan nanoparticles for oral insulin delivery","volume":"222","author":"Liu","year":"2016","journal-title":"J. Control Release"},{"key":"10.1016\/j.actbio.2025.06.016_bib0189","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12951-020-00662-x","article-title":"Enhanced oral delivery of insulin via the colon-targeted nanocomposite system of organoclay\/glycol chitosan\/Eudragit((R))S100","volume":"18","author":"Lee","year":"2020","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0190","first-page":"85","article-title":"Sources, production and commercial applications of fungal chitosan: a review","volume":"7","author":"Huq","year":"2023","journal-title":"J. Bioresour. Bioprod."},{"key":"10.1016\/j.actbio.2025.06.016_bib0191","doi-asserted-by":"crossref","first-page":"e6596","DOI":"10.1002\/ccr3.6596","article-title":"Anaphylaxis induced by intra-articular injection of chitosan: a case report and literature review","volume":"10","author":"Peng","year":"2022","journal-title":"Clin. Case Rep."},{"key":"10.1016\/j.actbio.2025.06.016_bib0192","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1021\/acsami.1c01089","article-title":"Metal-organic frameworks for drug delivery: a design perspective","volume":"13","author":"Lawson","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.actbio.2025.06.016_bib0193","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1021\/jacs.8b02089","article-title":"Acid-resistant mesoporous metal-organic framework toward oral insulin delivery: protein encapsulation, protection, and release","volume":"140","author":"Chen","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.actbio.2025.06.016_bib0194","doi-asserted-by":"crossref","first-page":"eabm4677","DOI":"10.1126\/sciadv.abm4677","article-title":"Efficient oral insulin delivery enabled by transferrin-coated acid-resistant metal-organic framework nanoparticles","volume":"8","author":"Zou","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.actbio.2025.06.016_bib0195","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jconrel.2024.11.045","article-title":"An environment-responsive platform based on acid-resistant metal organic framework for efficient oral insulin delivery","volume":"377","author":"Zhu","year":"2025","journal-title":"J. Control Release"},{"key":"10.1016\/j.actbio.2025.06.016_bib0196","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115049","article-title":"Biosafety of mesoporous silica nanoparticles; towards clinical translation","volume":"201","author":"L\u00e9rida-Viso","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2025.06.016_bib0197","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41578-021-00385-x","article-title":"Clinical translation of silica nanoparticles","volume":"6","author":"Janjua","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.actbio.2025.06.016_bib0198","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e20430","article-title":"Exploring mesoporous silica nanoparticles as oral insulin carriers: in-silico and in vivo evaluation","volume":"9","author":"Salarkia","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.actbio.2025.06.016_bib0199","doi-asserted-by":"crossref","first-page":"18077","DOI":"10.1021\/acsami.1c00580","article-title":"Virus-mimicking mesoporous silica nanoparticles with an electrically neutral and hydrophilic surface to improve the oral absorption of insulin by breaking through dual barriers of the mucus layer and the intestinal epithelium","volume":"13","author":"Zhang","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.actbio.2025.06.016_bib0200","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jcis.2020.08.010","article-title":"Zwitterion-functionalized mesoporous silica nanoparticles for enhancing oral delivery of protein drugs by overcoming multiple gastrointestinal barriers","volume":"582","author":"Gao","year":"2021","journal-title":"J. Colloid. Interface Sci."},{"key":"10.1016\/j.actbio.2025.06.016_bib0201","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1007\/s13346-023-01504-7","article-title":"Development of polysaccharide-coated layered double hydroxide nanocomposites for enhanced oral insulin delivery","volume":"14","author":"Pang","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.actbio.2025.06.016_bib0202","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41565-023-01565-2","article-title":"Oral nanotherapeutic formulation of insulin with reduced episodes of hypoglycaemia","volume":"19","author":"Hunt","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0203","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ijbiomac.2022.01.134","article-title":"Recent progress in polymeric non-invasive insulin delivery","volume":"203","author":"Sabbagh","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0204","first-page":"S472","article-title":"Passive delivery of protein drugs through transdermal route","volume":"46","author":"Chaulagain","year":"2018","journal-title":"Artif. Cell. Nanomed. B"},{"key":"10.1016\/j.actbio.2025.06.016_bib0205","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1208\/s12248-012-9400-3","article-title":"Variation of stratum corneum biophysical and molecular properties with anatomic site","volume":"14","author":"Mohammed","year":"2012","journal-title":"AAPS. J."},{"key":"10.1016\/j.actbio.2025.06.016_bib0206","doi-asserted-by":"crossref","first-page":"42461","DOI":"10.1021\/acsami.1c11533","article-title":"Insulin transdermal delivery system for diabetes treatment using a biocompatible ionic liquid-based microemulsion","volume":"13","author":"Islam","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.actbio.2025.06.016_bib0207","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jconrel.2022.01.019","article-title":"Noninvasive transdermal delivery of mesoporous silica nanoparticles using deep eutectic solvent","volume":"343","author":"Zhao","year":"2022","journal-title":"J. Control Release"},{"key":"10.1016\/j.actbio.2025.06.016_bib0208","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120784","article-title":"Accelerating transdermal delivery of insulin by ginsenoside nanoparticles with unique permeability","volume":"605","author":"Zou","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.actbio.2025.06.016_bib0209","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1039\/c2nr30651d","article-title":"Gold nanorods in an oil-base formulation for transdermal treatment of type 1 diabetes in mice","volume":"4","author":"Nose","year":"2012","journal-title":"Nanoscale"},{"key":"10.1016\/j.actbio.2025.06.016_bib0210","doi-asserted-by":"crossref","first-page":"6723","DOI":"10.1039\/C8TB01466C","article-title":"Poly(ester amide)-based hybrid hydrogels for efficient transdermal insulin delivery","volume":"6","author":"Zhang","year":"2018","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.actbio.2025.06.016_bib0211","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/10408398.2021.1952159","article-title":"Phytochemistry of ginsenosides: recent advancements and emerging roles","volume":"63","author":"Chopra","year":"2023","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"10.1016\/j.actbio.2025.06.016_bib0212","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1039\/C5TB02305J","article-title":"Ginsenoside nanoparticle: a new green drug delivery system","volume":"4","author":"Dai","year":"2016","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.actbio.2025.06.016_bib0213","doi-asserted-by":"crossref","first-page":"14792","DOI":"10.1021\/jacs.7b08710","article-title":"Ultrafast delivery of aggregation-induced emission nanoparticles and pure organic phosphorescent nanocrystals by saponin encapsulation","volume":"139","author":"Nicol","year":"2017","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.actbio.2025.06.016_bib0214","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1007\/s13346-021-01077-3","article-title":"Microneedle-based insulin transdermal delivery system: current status and translation challenges","volume":"12","author":"Zhao","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.actbio.2025.06.016_bib0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.140357","article-title":"High-performance silk fibroin\/hyaluronic acid interpenetrating network hydrogel microneedles for diabetes management","volume":"298","author":"Hua","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0216","doi-asserted-by":"crossref","first-page":"7725","DOI":"10.1021\/acs.chemmater.7b01804","article-title":"Glucose-responsive nanosystem mimicking the physiological insulin secretion via an enzyme-polymer layer-by-layer coating strategy","volume":"29","author":"Xu","year":"2017","journal-title":"Chem. Mater."},{"key":"10.1016\/j.actbio.2025.06.016_bib0217","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2337\/dbi23-0028","article-title":"Recent progress in glucose-responsive insulin","volume":"73","author":"Liu","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.actbio.2025.06.016_bib0218","first-page":"278","article-title":"Promising strategies for smart insulin delivery system: glucose-sensitive microneedle","author":"Chen","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.actbio.2025.06.016_bib0219","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41551-019-0508-y","article-title":"Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs","volume":"4","author":"Yu","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.actbio.2025.06.016_bib0220","first-page":"29","article-title":"Microneedle-array patch fabricated with enzyme-free polymeric components capable of on-demand insulin delivery","author":"Chen","year":"2019","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.actbio.2025.06.016_bib0221","article-title":"A dissolving and glucose-responsive insulin-releasing microneedle patch for type 1 diabetes therapy","volume":"9","author":"Zhang","year":"2021","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.actbio.2025.06.016_bib0222","first-page":"10","article-title":"\"Smart\" matrix microneedle patch made of self-crosslinkable and multifunctional polymers for delivering insulin on-demand","author":"Liu","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.actbio.2025.06.016_bib0223","series-title":"Carbohyd. Polym.","first-page":"348","article-title":"Intelligent microneedle patch based on functionalized alginate and chitosan for long-term self-regulated insulin delivery","author":"Wang","year":"2025"},{"key":"10.1016\/j.actbio.2025.06.016_bib0224","first-page":"26056","article-title":"Glucose-responsive microneedle patch with high insulin loading capacity for prolonged glycemic control in mice and minipigs","volume":"18","author":"Wang","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2025.06.016_bib0225","article-title":"A comprehensive review of intranasal insulin and its effect on the cognitive function of diabetics","volume":"13","author":"Gaddam","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.actbio.2025.06.016_bib0226","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1227423","article-title":"Synthesis of an insulin-loaded mucoadhesive nanoparticle designed for intranasal administration: focus on new diffusion media","volume":"14","author":"Jamshidnejad-Tosaramandani","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0227","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jconrel.2010.08.004","article-title":"Systemic delivery of insulin via the nasal route using a new microemulsion system: in vitro and in vivo studies","volume":"148","author":"Sintov","year":"2010","journal-title":"J. Control Release"},{"key":"10.1016\/j.actbio.2025.06.016_bib0228","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121565","article-title":"Intranasal delivery of insulin by self-emulsified nanoemulsion system: in vitro and in vivo studies","volume":"616","author":"Shah","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.actbio.2025.06.016_bib0229","doi-asserted-by":"crossref","unstructured":"Mucoadhesive microspheres of chitosan and polyvinyl alcohol as a carrier for intranasal delivery of insulin: in vitro and in vivo studies, 3 (2017).","DOI":"10.15406\/mojbb.2017.03.00030"},{"key":"10.1016\/j.actbio.2025.06.016_bib0230","article-title":"Unraveling the role of chitosan for nasal drug delivery systems: a review","volume":"5","author":"Kaur","year":"2023","journal-title":"Carbohydr. Polym. Tech."},{"key":"10.1016\/j.actbio.2025.06.016_bib0231","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/bab.1917","article-title":"Synthesis and characterization of thermosensitive hydrogel based on quaternized chitosan for intranasal delivery of insulin","volume":"68","author":"Bahmanpour","year":"2021","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.actbio.2025.06.016_bib0232","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/2230-973X.176456","article-title":"Insulin delivery methods: past, present and future","volume":"6","author":"Shah","year":"2016","journal-title":"Int. J. Pharm. Investig."},{"key":"10.1016\/j.actbio.2025.06.016_bib0233","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","article-title":"Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0234","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0169-409X(98)00074-X","article-title":"Inhaled insulin","volume":"35","author":"Patton","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2025.06.016_bib0235","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s11095-008-9562-y","article-title":"Role of particle size in phagocytosis of polymeric microspheres","volume":"25","author":"Champion","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.actbio.2025.06.016_bib0236","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14112533","article-title":"Instability challenges and stabilization strategies of pharmaceutical proteins","volume":"14","author":"Akbarian","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.actbio.2025.06.016_bib0237","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114173","article-title":"Nano-delivery to the lung - by inhalation or other routes and why nano when micro is largely sufficient?","volume":"183","author":"Forest","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2025.06.016_bib0238","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1021\/acs.molpharmaceut.4c00128","article-title":"Solid lipid nanoparticles for pulmonary delivery of biopharmaceuticals: a review of opportunities, challenges, and delivery applications","volume":"21","author":"Alwani","year":"2024","journal-title":"Mol. Pharmaceut."},{"key":"10.1016\/j.actbio.2025.06.016_bib0239","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.bbamem.2017.04.019","article-title":"Pulmonary surfactant and nanocarriers: toxicity versus combined nanomedical applications","volume":"1859","author":"Hidalgo","year":"2017","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.actbio.2025.06.016_bib0240","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijpharm.2007.03.009","article-title":"Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization","volume":"340","author":"Liu","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.actbio.2025.06.016_bib0241","first-page":"643","article-title":"Engineered microparticles of hyaluronic acid hydrogel for controlled pulmonary release of salbutamol sulphate","author":"Nikjoo","year":"2023","journal-title":"Int. J. Pharmaceut."},{"key":"10.1016\/j.actbio.2025.06.016_bib0242","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0168-3659(03)00263-3","article-title":"Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs","volume":"91","author":"Surendrakumar","year":"2003","journal-title":"J. Control Release"},{"key":"10.1016\/j.actbio.2025.06.016_bib0243","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jconrel.2011.08.008","article-title":"Microencapsulated chitosan nanoparticles for pulmonary protein delivery: in vivo evaluation of insulin-loaded formulations","volume":"157","author":"Al-Qadi","year":"2012","journal-title":"J. Control Release"},{"key":"10.1016\/j.actbio.2025.06.016_bib0244","article-title":"Preparation and evaluation of oral insulin nanocapsule delivery systems","volume":"290","author":"Zhang","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.actbio.2025.06.016_bib0245","article-title":"Permeation enhancer decorated nanoparticles for oral delivery of insulin: manipulating the surface density of borneol and PEG for absorption barriers","author":"Yang","year":"2024","journal-title":"Biomater. Sci."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706125004234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706125004234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T07:33:46Z","timestamp":1776843226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706125004234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":245,"alternative-id":["S1742706125004234"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2025.06.016","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nano-based therapy for type 1 diabetes: from immuno-intervention to insulin delivery","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2025.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of Acta Materialia Inc.","name":"copyright","label":"Copyright"}]}}